![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/7/73/Milrinone.svg/640px-Milrinone.svg.png&w=640&q=50)
Milrinone
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Milrinone?
Summarize this article for a 10 year old
Milrinone, sold under the brand name Primacor, is a pulmonary vasodilator[2] used in patients who have heart failure. It is a phosphodiesterase 3 inhibitor that works to increase the heart's contractility and decrease pulmonary vascular resistance. Milrinone also works to vasodilate which helps alleviate increased pressures (afterload) on the heart, thus improving its pumping action. While it has been used in people with heart failure for many years, studies suggest that milrinone may exhibit some negative side effects that have caused some debate about its use clinically.[3][4]
![]() | |
Clinical data | |
---|---|
AHFS/Drugs.com | Monograph |
MedlinePlus | a601020 |
Routes of administration | IV only |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 100% (as IV bolus, infusion) |
Protein binding | 70 to 80% |
Metabolism | Liver (12%) |
Elimination half-life | 2.3 hours (mean, in CHF) |
Excretion | Urine (85% as unchanged drug) within 24 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.071.709 ![]() |
Chemical and physical data | |
Formula | C12H9N3O |
Molar mass | 211.224 g·mol−1 |
3D model (JSmol) | |
Density | 1.344 g/cm3 |
Melting point | 315 °C (599 °F) |
| |
| |
(verify) |
Overall, milrinone supports ventricular functioning of the heart by decreasing the degradation of cyclic adenosine monophosphate (cAMP) and thus increasing phosphorylation levels of many components in the heart that contribute to contractility and heart rate. Milrinone is used as a drug that causes positive inotropy and it will lead to an increased force of contraction. Milrinone use following cardiac surgery has been under some debate because of the potential increase risk of postoperative atrial arrhythmias.[5] However, in the short term milrinone has been deemed beneficial to those experiencing heart failure and an effective therapy to maintain heart function following cardiac surgeries. There is no evidence of any long term beneficial effects on survival.[6] In critically ill patients with evidence of cardiac dysfunction there is limited good quality evidence to recommend its use.[7]
Milrinone is administered IV only and eliminated unchanged in the urine. Dose adjustment is required for patients with renal impairment.[8]